Could a cholesterol shot stop a first heart attack?
NCT ID NCT07734753
First seen Jul 29, 2026 · Last updated Sep 11, 2026 · Updated 2 times
Summary
This study looks at whether alirocumab, a drug that lowers cholesterol, can reduce the risk of heart attack, stroke, or death in people who have hardened arteries but have never had a heart attack or stroke before. Researchers will analyze data from routine medical care to compare those who take alirocumab with those who do not. The goal is to see if starting this treatment earlier could prevent a first major cardiovascular event.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Alirocumab, a PCSK9 inhibitor drug that lowers cholesterol
- What this could lead to
- If alirocumab proves effective, it could support using this cholesterol-lowering drug earlier in people with artery disease who have not yet had a heart attack or stroke.
- What could go wrong
- This is an observational analysis of existing medical records, not a controlled experiment, so results may be influenced by unmeasured differences between groups. The drug also requires regular injections and can cause injection-site reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
4,006 people
The number who actually took part.
- Started
-
Jul 2025
- Finished
-
Aug 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The eligible population includes adults aged ≥18 years with documented ASCVD and no history of myocardial infarction, ischemic stroke, or hospitalization for unstable angina.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults aged ≥18 years with documented ASCVD between January 1, 2016, and September 30, 2024. * No history of myocardial infarction, ischemic stroke, or hospitalization for unstable angina on or before the index date. * Minimum of 12 months of continuous healthcare data availability prior to the index date * No exposure to any PCSK9 inhibitor in the 2 years preceding the index date. Exclusion Criteria: \- Participants with a history of prior ischemic events. The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease without prior ischemic events are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Sanofi
Amsterdam, 1105 BP, Netherlands
More trials for these conditions
Other studies related to the condition(s) this trial covers.